Liminatus Pharma to Acquire InnocsAI in Transformative Reverse Merger, Issuing 1.6 Billion Shares

summarizeSummary

Liminatus Pharma has entered a definitive agreement to acquire InnocsAI LLC, a clinical-stage oncology company, in a highly dilutive reverse merger that will issue 1.6 billion new shares and fundamentally transform the company's pipeline and ownership structure.

check_boxKey Events

• Definitive Merger Agreement Signed

  Liminatus Pharma, Inc. entered into a Merger Agreement on May 17, 2026, to acquire InnocsAI LLC, a Delaware limited liability company, in a highly transformative transaction.

• Massive Share Issuance and Dilution

  The aggregate consideration for InnocsAI is 1,600,000,000 shares of Liminatus Pharma's common stock, issued at $0.20 per share, plus contingent value rights. This represents a $320 million transaction value, which is approximately 38 times the company's current market capitalization, indicating extreme dilution for existing shareholders.

• Acquisition of Clinical-Stage Oncology Pipeline

  The acquired assets include a portfolio of oncology-focused biologic and cellular therapy programs, notably IBC101, a bivalent CAR-T cell therapy candidate authorized for a Phase 1/2a clinical study in South Korea, and preclinical solid tumor CAR-T programs.

• Related-Party Transaction

  Chris Kim, the CEO and a director of Liminatus Pharma, is also the CEO and controlling member of Valetudo Therapeutics LLC, which is a member of InnocsAI, indicating a related-party transaction.

auto_awesomeAnalysis

This 8-K details a definitive merger agreement for Liminatus Pharma to acquire InnocsAI LLC, a move that fundamentally reshapes the company. For a pre-clinical biotech facing 'going concern' warnings, acquiring a clinical-stage oncology pipeline (including a Phase 1/2a CAR-T candidate) represents a critical strategic pivot and potential lifeline. However, the consideration involves issuing 1.6 billion new shares at $0.20 each, totaling $320 million, which is an extraordinary amount compared to the company's current $8.4 million market capitalization. This transaction will result in extreme dilution for existing shareholders, effectively functioning as a reverse merger where InnocsAI's owners will gain substantial control. The involvement of Liminatus's CEO in a selling entity also adds a layer of complexity. This is a high-stakes gamble to inject new assets and extend the company's runway, but at a significant cost to current equity holders.